Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Nanobiotix S.A. ADR
(NQ:
NBTX
)
5.280
+0.350 (+7.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanobiotix S.A. ADR
< Previous
1
2
3
4
5
Next >
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
April 08, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
April 07, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
March 30, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
March 16, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
February 10, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
February 09, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
January 26, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
January 11, 2022
From
Nanobiotix
Via
Business Wire
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
January 10, 2022
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
January 05, 2022
From
NANOBIOTIX
Via
Business Wire
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
January 04, 2022
From
Nanobiotix
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
December 08, 2021
From
Nanobiotix
Via
Business Wire
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
November 17, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
November 09, 2021
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
November 08, 2021
From
Nanobiotix
Via
Business Wire
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
November 03, 2021
From
Nanobiotix
Via
Business Wire
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
October 24, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Provides Third Quarter Operational and Financial Update
October 20, 2021
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
October 08, 2021
From
Nanobiotix
Via
Business Wire
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
October 06, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
September 28, 2021
From
NANOBIOTIX
Via
Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
September 09, 2021
From
Nanobiotix
Via
Business Wire
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
September 08, 2021
From
NANOBIOTIX S.A.
Via
Business Wire
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
NANOBIOTIX
Via
Business Wire
Nanobiotix Provides Second Quarter Operational and Financial Update
July 20, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
June 30, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
June 07, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
June 03, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board to Support Global Expansion
June 01, 2021
From
NANOBIOTIX
Via
Business Wire
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
May 26, 2021
From
NANOBIOTIX
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.